In-vivo data to the highest technical and scientific standards
Scantox is the leading Nordic preclinical GLP accredited CRO – Contract Research Organization.
Based on decades of experience we are a trusted partner for in-vivo preclinical research services for the pharmaceutical and medical device industries. The Scantox services enable clients to progress their drug or device development based on consistent, high-quality solid data to the highest technical and scientific standards.
Our main focus is on pharmacology and regulatory toxicology and based on decades of experience, we are a trusted partner for product development services within the pharmaceutical and medical device industries.
Our services span from handling and formulating test items over in-life studies to histopathology producing tissue slides for reviewing by our experienced team of pathologists.
Furthermore, we offer all standard clinical pathology analysis as well as specialized biomarkers that are required according to international toxicology guidelines. Dose formulation analysis, bioanalysis as well as safety pharmacology testing are also part of our core capabilities.
31 August 2023 -- Scantox A/S (“Scantox” or the “Company”), the leading Nordic GLP-compliant pre-clinical contract research organization (“CRO”), headquartered in Denmark and since 2021 owned by Impilo, is pleased to announce the acquisition of Q&Q Labs AB located...
July 7th – Scantox Group, a leading provider of nonclinical services in Europe, has named Andy Brown as Group Chief Commercial Officer with the overall responsibility of growing sales within toxicology, discovery and lab services and fostering positive relationships...
Scantox is pleased to announce that we are exclusive distributors of advanced preclinical models, including the BRGSF-HIS and advanced humanized immune checkpoint models from genOway in Demark, Sweden, Norway and Finland. The genOway BRGSF-HIS mouse possesses the most...
Join our team of professionals
We are continuously looking for new talents to join our teams in Denmark and Sweden.
With over 20 years of extensive experience, we are considered global leaders within minipig toxicology studies, with studies conducted in Göttingen Minipigs.
We work to the highest scientific standards, and engage with partners in scientific collaborations to provide the best scientific results and highest degree of knowledge.
Scantox is a trusted partner for product development services within the pharmaceutical, biotech and medical devices industries, and a world leader in scientific research based on Göttingen Minipigs.
The Scantox Name
The Scantox name dates back to 1977. It holds the story of our geographic origination – SCANdinavia – and of our original key area of expertise – TOXicology.
Today Scantox is an international corporation, and our areas of expertise have expanded into a vast portfolio of preclinical study types. But our roots and values remain.
We are Scantox.
The Scantox team is passionate about our common mission to improve the health of people, by creating life-changing scientific results. Every day.
Founded in 1977, Scantox is today owned by the Nordic based investment company Impilo.
About Scantox Group
Scantox is the leading Nordic preclinical GLP-accredited Contract Research Organization, focused on pharmacology and regulatory toxicology. We are headquartered in Denmark, in the same location as where the company was originally founded in 1977. In addition Scantox has several subsidiaries in Sweden.
Scantox is specialized in preclinical contract research services. Our scientific work enables pharmaceutical and biotechnology companies to progress drug development projects, based on solid high-quality data. Core competencies within the Scantox Group include Explorative and efficacy studies, PK-studies, general toxicology studies including Juvenile & EFD, local tolerance studies, wound healing studies and vaccines. GLP and GMP compliant. Scantox’ core business is studies within the Preclinical phase, but we also extend our expertise into studies in early discovery as well as preclinical tests that overlap into phases 1 and 2.
As one of the most experienced preclinical service providers, our in-vivo work is backed by decades of experience. This makes Scantox a highly trusted partner for product development services within the pharmaceutical, biotech and medical devices industries, and a globally recognized leader for our expertise and long experience with the Göttingen Minipig. Our services enable clients to progress their drug or device development based on solid data to the highest technical and scientific standards.
Scantox is today owned by Impilo, the leading Nordic healthcare investment company.